Effectiveness and Safety of Botulinum Toxin Type A Injection for Scar Prevention: A Systematic Review and Meta-analysis

2019 ◽  
Vol 43 (5) ◽  
pp. 1241-1249 ◽  
Author(s):  
Yin Wang ◽  
Jun Wang ◽  
Jinsong Zhang ◽  
Chao Hu ◽  
Fei Zhu
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Scar Prevention

scholarly journals CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis

Cephalalgia ◽  
2021 ◽  
pp. 033310242110181
Author(s):  
Florian Frank ◽  
Hanno Ulmer ◽  
Victoria Sidoroff ◽  
Gregor Broessner
Keyword(s):  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Botulinum Toxin ◽  
Response Rate ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Response Rates ◽  
Botulinum Toxin Type ◽  
Odds Ratios

Background The approval of monoclonal antibodies for prevention of migraine has revolutionized treatment for patients. Oral preventatives are still considered first line treatments as head-to-head trials comparing them with antibodies are lacking. Methods The main purpose of this study was to provide a comparative overview of the efficacy of three commonly prescribed migraine preventative medication classes. For this systematic review and meta-analysis, we searched the databases CENTRAL, EMBASE, and MEDLINE until 20 March 2020. We included RCTs reporting the 50% response rates for topiramate, Botulinum Toxin Type A and monoclonal antibodies against CGRP(r). Studies were excluded if response rates were not reported, treatment allocation was unclear, or if study quality was insufficient. Primary outcome measure were the 50% response rates. The pooled odds ratios with 95% confidence intervals were calculated with the random effects model. The study was registered at PROSPERO (CRD42020222880). Findings We identified 6552 reports. Thirty-two were eligible for our review. Studies assessing monoclonal antibodies included 13,302 patients and yielded pooled odds ratios for the 50% response rate of 2.30 (CI: 2.11–2.50). Topiramate had an overall effect estimate of 2.70 (CI: 1.97–3.69) with 1989 included patients and Botulinum Toxin Type A achieved 1.28 (CI: 0.98–1. 67) with 2472 patients included. Interpretation Topiramate, botulinum toxin type A and monoclonal antibodies showed higher odds ratios in achieving a 50% response rate compared to placebo. Topiramate numerically demonstrated the greatest effect size but also the highest drop-out rate.

scholarly journals The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051989586 ◽  
Author(s):  
Shuchao Zhai ◽  
Botao Huang ◽  
Kai Yu
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Knee Osteoarthritis ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Painful Knee

Objective A systematic review and meta-analysis was carried out to evaluate the efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis. Methods The EMBASE and MEDLINE databases were searched to identify randomized controlled trials (RCTs) of Botulinum Toxin Type A in the treatment of painful knee osteoarthritis. The references of included literature were also searched. Results Five articles involving 5 RCTs including 314 patients were included in this analysis. There was a significant difference between Botulinum Toxin Type A and placebo in the visual analog scale (VAS) pain scale and Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) questionnaire score in both the short-term (≤4 weeks) and long-term (≥8 weeks) treatment period. There were no serious adverse events in the Botulinum Toxin Type A groups. Conclusions This meta-analysis suggests that Botulinum Toxin Type A is effective and safe in the painful knee OA treatment. However, high-quality randomized controlled studies are still needed to further confirm our findings.

Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 40 (5) ◽  
pp. 769-777 ◽  
Author(s):  
Zhenhua Jia ◽  
Haibin Lu ◽  
Xiaonan Yang ◽  
Xiaolei Jin ◽  
Rongwei Wu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Adverse Events ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Facial Rejuvenation

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

2020 ◽  
Vol 21 (3-4) ◽  
pp. 281-293
Author(s):  
Daniel Machado ◽  
Ana Luiza Cabrera Martimbianco ◽  
Sandra Kalil Bussadori ◽  
Rafael Leite Pacheco ◽  
Rachel Riera ◽  
...  
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Temporomandibular Disorders ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type
Sign in / Sign up

Export Citation Format

Share Document